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INTRODUCTION
Placenta is an organ that brings maternal and fetal blood circulations to proximity, allowing mutual interchange of nutrients and waste products. On the other hand, placenta forms a barrier to protect fetus against harmful endo-and exogenous compounds from maternal circulation. As a barrier, the human and rodent placenta had for long been supposed to present only a mechanical obstruction formed by fetal endothelia, basal membranes and syncytiotrophoblast. However, over the last two decades, variety of metabolizing enzymes and drug efflux transporters of the ATP-binding cassette (ABC) transporter family have been localized in placental trophoblast (Marin et al., 2004; Syme et al., 2004) . These proteins are believed to strengthen, in an active and capacity limited manner, placental barrier role and help in protecting the fetus.
Drug efflux transporters of the ABC family are membrane-embedded proteins that limit intracellular concentration of substrates by pumping them out of cell through an active, energy dependent mechanism (Schinkel and Jonker, 2003) . The most intensively studied drug efflux transporters to date have been P-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins 1 and 2 (ABCC1, ABCC2), all of which were found to be responsible for the phenomenon of multidrug resistance in cancer therapy (Fischer et al., 2005) . In addition, due to their extensive distribution in non-tumorous tissues and wide substrate specificity, these proteins significantly affect body disposition of many clinically used drugs. With respect to expression, regulation, function and clinical relevance, the best described of placental ABC transporters to date is P-glycoprotein (Ceckova-Novotna et al., 2006) .
Breast cancer resistance protein (BCRP) is the most recently described member of the ABC transporter superfamily (Doyle et al., 1998) . Its expression has been assessed in many tissues and cells including blood-brain barrier, placenta, intestine, various tumors and "side This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on June 29, 2006 as DOI: 10.1124 at ASPET Journals on May 3, 2016 jpet.aspetjournals.org Downloaded from JPET #105023 5 population" of stem cells (Staud and Pavek, 2005) . Since its tissue distribution and substrate specificity overlap noticeably with that of P-glycoprotein (P-gp), it is generally believed that these transporters share similar role in protecting pharmacological sanctuaries such as brain and fetus.
Considerable levels of BCRP/Bcrp expression have been detected in placentas of various species. In humans, placental BCRP expression was found to be approximately 10-times higher than that of P-gp . Given the expression pattern and the broad range of substrates including exogenous (drugs, toxins) and endogenous (steroid conjugates, porphyrins) compounds (Staud and Pavek, 2005) , it is reasonable to assume that BCRP may be an important component of the placental barrier. Kolwankar et al (Kolwankar et al., 2005) confirmed BCRP function in microvillous membrane vesicles of the human placenta. In addition, we have recently described BCRP expression, localization and function in an in vitro placental model, BeWo cell line . The only functional in vivo experiments proposing Bcrp activity in the placenta were performed by Jonker et al in transgenic mice (Jonker et al., 2000; Jonker et al., 2002) . Nevertheless, transport activity of this efflux protein and its role in transplacental pharmacokinetics has not been fully evaluated to date.
Due to technical constraints and ethical issues, direct investigation of placental drug transfer under in vivo conditions in human is not feasible; therefore, several alternative experimental methods have been developed to assess potential risk that drugs in maternal circulation present to the fetus (Sastry, 1999) . Among these, cell cultures and perfused placentas of various species are widely employed models for mechanistic studies to describe transplacental pharmacokinetics, including transport mechanisms and biotransformation. The dually perfused rat placenta, in particular, is a well established model that has been successfully employed to investigate placental physiology and pharmacology (Stulc et al., This article has not been copyedited and formatted. The final version may differ from this version. Kertschanska et al., 2000) . In our earlier studies, we employed this experimental model to evaluate functional activity of P-gp in the rat placenta (Pavek et al., 2001; Pavek et al., 2003) .
The aim of the present study was to assess the effect of Bcrp on transplacental passage of its substrates. We investigated Bcrp activity both in vitro, using HRP-1 rat placental cell line, and in situ in dually perfused rat term placenta. Using these techniques, we describe Bcrp as an active component of the rat placental barrier that limits maternal-to-fetal and facilitates fetal-to-maternal transport of its substrates. This article has not been copyedited and formatted. The final version may differ from this version. 
Cell cultures
For in vitro accumulation studies, HRP-1 rat trophoblast cells (Soares et al., 1987) , received as a generous gift from Dr. Michael Soares at the University of Kansas Medical Center, were employed. They were maintained in RPMI-1640 culture medium supplemented with 10% fetal bovine serum, 100 units/ml of penicillin, 100 µg/ml of streptomycin, 1 mM sodium pyruvate and 50 µM β-mercaptoethanol. Cells from passages 15-25 were used in experiments described herein.
Animals
All experiments were approved by the Ethical Committee of the Faculty of Pharmacy (Hradec Kralove, Charles University in Prague) and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals, 1996 and the European Convention for This article has not been copyedited and formatted. The final version may differ from this version. Republic) and were maintained in 12/12-h day/night standard conditions with water and pellets ad libitum. Experiments were performed on day 21 of gestation. Fasted rats were anesthetized with pentobarbital (Nembutal, Abbott Laboratories, North Chicago, IL) in a dose of 40 mg/kg administered into the tail vein.
RNA isolation and RT-PCR analysis
Placentas and kidneys were collected on day 21 of gestation from 5 rats. Five randomly selected placentas from each animal were dissected free of maternal tissues and fetal membranes. Immediately after dissection, the organs were frozen in liquid nitrogen and stored at -70°C until analysis. RNA isolation and reverse transcription were performed as described previously (Novotna et al., 2004) . Sequences of mRNAs for target genes were obtained from NCBI database; primers for mdr1a, mdr1b and bcrp genes were designed using the Vector NTI Suite software (Informax, Bethesda, MD, USA) and are given in Table 1. RT-PCR analysis was performed on iCycler iQ (Bio-Rad, Hercules, CA, USA). cDNA was amplified with HotStart Taq polymerase under the following conditions: 3mM MgCl 2 , 0.2mM dNTP, 0.03 U/µl polymerase, SybrGreen I in 1:100,000 dilution, 0.3 µM each primer; the temperature profile was 95°C for 14 min; 50 times: 95°C for 15s, 60°C for 20s, 72°C for 20s, 72°C for 5 min; melting curve program 72-95°C. Each sample of cDNA was amplified in duplicates. The PCR products were separated by electrophoresis on 2% agarose gel in the presence of ethidium bromide and visualized under ultraviolet light and compared with low molecular weight DNA ladder (25-766bp) (New England BioLabs, Herts, UK). This article has not been copyedited and formatted. The final version may differ from this version. 
Western blot analysis
Cell membrane fractions of placenta tissues and whole cell lysates were prepared as described previously (Novotna et al., 2004; . Protein contents were determined by BCA TM Protein Assay Detection Kit (Pierce, Rockford, IL, USA). Samples containing 100 µg of cell lysate protein or 40 µg of tissue cell membrane were subjected to electrophoresis on 8% SDS-polyacrylamide gels and subsequently electrotransferred onto 
Immunohistochemical localization of Bcrp in the rat term placenta
Preparation of rat placental tissue was performed as described previously (Pavek et al., 2003) . The antigen (Bcrp) was unmasked by heating the specimens in sodium citrate buffer (pH 6.0) for two-times 8 minutes in a microwave oven at 750W. Slides were incubated with a polyclonal primary antibody for BCRP (M-70; Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:10 in BSA (bovine serum albumin) for 15 to 18 h at 4°C. Subsequently, the slides were developed with a secondary antibody -goat anti-rabbit IgG conjugated to peroxidase-labelled polymer (DAKO EnVision TM , Carpinteria, USA) for 30 minutes. The This article has not been copyedited and formatted. The final version may differ from this version. 
Cellular uptake experiments
HRP-1 cells were seeded on 24-well culture plates (1x10 5 per well) 2 days prior to experiment. Cell culture medium was removed and cells were washed twice with 500 µl prewarmed PBS. Cells were then preincubated in OPTI-MEM medium with or without inhibitor (1 µM GF120918, 1 µM Ko143, 25 µM verapamil or 1 µM PSC833) at 37°C in 5 % CO 2 for 60 min before fluorescent substrate, BODIPY FL prazosin (500 nM), was added.
Accumulation was allowed for 2 h at 37°C and was arrested by prompt cooling on ice and removal of medium. Cells were washed with ice-cold PBS, lyzed in 1% SDS and fluorescence was measured after 24 hours (Genios Plus, Tecan, Austria). Fluorescence of each well was related to protein content as assessed by BCA TM Protein Assay Detection Kit.
Dual perfusion of the rat placenta
The method of dually perfused rat placenta was used as described previously (Pavek et al., 2003) . Briefly, one uterine horn was excised and submerged in heated Ringer saline. A catheter was inserted into the uterine artery proximal to the blood vessel supplying a selected placenta and connected with the peristaltic pump. Krebs' perfusion liquid containing 1 % albumin was brought from the maternal reservoir at a rate of 1 ml/min. The uterine vein, This article has not been copyedited and formatted. The final version may differ from this version. including the anastomoses to other fetuses, was ligated behind the perfused placenta and cut so that maternal solution could leave the perfused placenta. The selected fetus was separated from the neighboring ones by ligatures. The umbilical artery was catheterized using 24-gauge catheter connected to the fetal reservoir and perfused at a rate of 0.5 ml/min. The umbilical vein was catheterized in a similar manner and the selected fetus was removed. Before the start of each experiment, the fetal vein effluent was collected into pre-weighted glass vials to check a possible leakage of perfusion solutions from the placenta. In the case of leakage, the experiment was terminated. Maternal and fetal perfusion pressures were maintained at levels close to physiological values and monitored continuously throughout the perfusion experiments as described before (Pavek et al., 2001) . At the end of experiment, placenta was perfused with radioactivity-free buffer for 10 min, excised from the uterine tissue, dissolved in tissue solubilizer (Solvable, PerkinElmer, Boston, MA) and its radioactivity measured in order to detect tissue-bound cimetidine.
Two types of perfusion systems were employed in this study:
(1) For pharmacokinetic analysis of concentration-dependent transplacental passage of cimetidine, both maternal and fetal sides of the placenta were perfused in open-circuit systems, without recirculation of the perfusate. Cimetidine was added to the maternal (in maternal-to-fetal studies) or fetal (in fetal-to-maternal studies) reservoir immediately after successful surgery followed by approximately 10 min stabilization period before sample collection started (time 0). Fetal effluent was sampled into pre-weighted vials in 5-minute intervals and analyzed for [ 3 H]cimetidine.
(2) To investigate the capability of Bcrp to remove its substrate from fetal circulation, both maternal and fetal sides of the placenta were infused with equal concentrations of cimetidine and after 10 min stabilization period, the fetal perfusate (10 ml) was recirculated for 60 min. Samples (200 µl) were collected every 10 minutes from the maternal and fetal This article has not been copyedited and formatted. The final version may differ from this version. investigations of maternal/fetal concentration ratio; any net transfer of the drug implies transport against a concentration gradient and is evidence for active transport.
Effect of cimetidine inflow concentrations and BCRP inhibitors on transplacental clearance
To investigate the effect of cimetidine concentrations on maternal-to-fetal and fetal-tomaternal clearances, cimetidine and [ 3 H]cimetidine as a tracer were added to the maternal or fetal reservoir, respectively, in one of the following concentrations: 0.005, 0.1, 1, 30, 100 or 1000 µM. The inflowing cimetidine concentration was maintained constant for the duration of the experiment; transplacental clearances of cimetidine were calculated for every concentration from all measured intervals as described below.
To study the effect of BCRP and P-gp inhibitors, fumitremorgin C (2 µM), GF120918
(2 µM), cyclosporine (10 µM) or verapamil (25 µM) was added to the maternal or fetal reservoir in the 10 th minute of perfusion. Subsequently, transplacental clearance of cimetidine in the period of 0-10 min (without inhibitor) was compared with that in 20-30 min (with inhibitor), leaving the mid-interval of 10-20 min as a stabilization period to achieve a new steady-state after addition of inhibitor. This experimental setup allows for direct observations of inhibitor effect in one animal, reducing possible interindividual variability. Total maternal-to-fetal transplacental clearance (Cl Tmf ) of cimetidine normalized to placenta weight was calculated according to equation 1.
Pharmacokinetic analysis of efflux transport activity in the placenta
where C fv is the concentration of cimetidine in the umbilical vein effluent, Q f is the umbilical flow rate, C ma is the concentration of cimetidine in the maternal reservoir and w p is the wet weight of the placenta.
In fetal-to-maternal studies, the ability of the placenta to remove cimetidine from the fetal circulation was expressed as extraction ratio (ER) using equation 2 (Shargel and Yu, 1993) :
where C fa is the concentration of cimetidine in the fetal reservoir entering the perfused placenta via the umbilical artery. Total fetal-to-maternal clearance normalized to placenta weight (Cl Tfm ) was calculated according to equation 3. 
To distinguish between passive and active components of the transplacental movement, the following concept was applied ( Fig. 1 ). Assuming the total transplacental passage of cimetidine being a function of passive diffusion and efflux activity of BCRP, the total transplacental clearance in maternal-to-fetal (Cl Tmf ) and fetal-to-maternal (Cl Tfm ) direction is described by equations 4 and 5, respectively: 
where Cl pd is clearance of passive diffusion and Cl efflux expresses the efflux activity of the transporter. Since Cl efflux is a capacity-limited (non-linear) process, it can be expressed in terms of Michaelis-Menten kinetics:
where V max is the maximal velocity of the transport, K m is the concentration at which half the maximal velocity is reached and C ma(fa) is substrate concentration in maternal (C ma ) or fetal (C fa ) circulation.
In maternal-to-fetal studies, adding Cl efflux into (4) yields the following equation which was used to fit clearance vs inflow concentration data:
In analogy, when the effect of fetal inflow concentrations on fetal-to-maternal clearance was investigated, data were fitted by the following equation: 
Statistical analysis
For each group of placental perfusion experiments, the number of animals was n ≥ 4.
Cellular uptake studies are based on n = 4. One-way ANOVA followed by Bonferroni test or Student's t-test were used where appropriate to assess statistical significance. Differences of p < 0.05 were considered statistically significant. This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Expression of Bcrp and P-gp in rat placenta and HRP-1 cells
RT-PCR and Western blotting were employed to investigate the expression of Bcrp and Pgp in the rat placenta and HRP-1 cell line and compared with that in kidney as a positive control (Tanaka et al., 2005) . The bands corresponding to 329, 331 and 188 bp for mdr1a, mdr1b and Bcrp, respectively, were visualized under the ultraviolet light ( Fig. 2A) .
Expression of Bcrp was detected in rat kidney, placenta and HRP-1 cell line samples. In contrast, expression of both mdr1a and mdr1b (coding for P-gp) was detected only in rat kidney and placenta but not in HRP-1 cell line. Similarly, application of polyclonal anti-Abcg2 antibody M-70 revealed significant levels of Bcrp in the rat placenta, kidneys and HRP-1 cells. Using C219 monoclonal antibody we confirmed the expression of P-gp in the rat placenta and kidneys only while no signal for P-gp was detected in HRP-1 cell lysate (Fig.   2B ).
Immunohistochemical localization of Bcrp in the rat term placenta
Localization of Bcrp expression in the rat term placenta was investigated by immunohistochemistry at the light microscopy level. Four different placentas (gestation day 21) were used for the experiments. The rat placenta is composed of two morphologically different zones, the junctional zone (maternal blood spaces separated by trophoblastic trabeculae that do not contain fetal blood vessels) and the labyrinth zone (maternal blood separated from fetal blood vessels by trophoblast cells). Bcrp was detected in the inner layers of the syncytiotrophoblast (layers II and III) of the labyrinth zone only (Fig. 3) 
Bcrp efflux activity in HRP-1 cell line
To investigate Bcrp and/or P-gp activity in HRP-1 placental cells, BODIPY FL prazosin (500 nM) as a common substrate of BCRP and P-gp was added to the cells and the effect of Bcrp and/or P-gp inhibitors was observed. In agreement with gene expression data, only BCRP specific inhibitor, Ko143 (1 µM), and dual BCRP and P-gp inhibitor, GF120918 (1 µM), increased BODIPY FL prazosin accumulation by more than 100% (p < 0.05). In contrary, P-gp specific inhibitors, PSC833 (1 µM) and verapamil (25 µM) did not affect BODIPY FL prazosin accumulation suggesting undetectable activity of P-gp in the HRP-1 cell line (Fig. 4) .
Consistency of perfusion experiments
To determine a steady-state period suitable for inhibitor studies in both maternal-to-fetal and fetal-to-maternal experiments, placenta was first perfused with 0.1 µM cimetidine for 50 minutes. If no inhibitor was added, we observed steady clearances for the whole period. When a BCRP inhibitor was added to the maternal perfusate in the 10 th minute of perfusion, it took about 5-10 minutes to achieve a new steady-state (data not shown). Therefore, to evaluate the effect of inhibitor on cimetidine transplacental passage, samples from 0-10 min interval of perfusion were averaged and compared to those collected in 20-30 min interval.
Effect of BCRP and P-gp inhibitors on transplacental passage of cimetidine
To test interactions of cimetidine with placental Bcrp or P-gp, dual and/or specific inhibitors of these transporters were added to maternal reservoir. Addition of BCRP inhibitors, GF120918 (2 µM) or fumitremorgin C (2 µM), caused significant change in transplacental clearance of cimetidine (Fig. 5) . Interaction of cimetidine with human P-gp has recently been ruled out using MDR1-transfected MDCKII and LLC-PK1 cell lines (Pavek et Although these compounds increased maternal-to-fetal clearance of rhodamine123, a P-gp substrate, in our previous study (Pavek et al., 2003) , they did not interfere with transport of cimetidine. Therefore, transplacental passage of cimetidine does not seem to be affected by Pgp and cimetidine can be used as a marker compound to functionally analyze efflux activity of Bcrp in the rat placenta. Inhibitory effect observed after addition of GF120918 may be ascribed to Bcrp blockade only, although we cannot exclude possible contribution of other, yet unidentified GF-sensitive cimetidine transporter.
Effect of inflow cimetidine concentrations on transplacental clearance
Cimetidine was infused to maternal or fetal side of the placenta in one of the following concentrations: 0.005, 0.1, 1, 30, 100, or 1000 µM. In both maternal-to-fetal and fetal-tomaternal transport studies, increase in cimetidine concentration caused significant change in transplacental clearance, confirming non-linearity of the process and involvement of a capacity-limited mechanism (Figs. 6 and 7) . Furthermore, addition of a BCRP inhibitor significantly affected clearances at lower cimetidine concentrations while at concentrations above 30 µM, inhibitor was rather ineffective.
Fitting experimental data with equations 7 and 8 provided pharmacokinetic parameters describing passive and Bcrp-mediated transplacental passage of cimetidine (Table 2) This has been experimentally achieved in both maternal-to-fetal and fetal-to-maternal studies when cimetidine concentration was increased to 1000 µM. Furthermore, since addition of inhibitor caused no change in transplacental clearance of 1000 µM cimetidine (see Figs. 6 and 7), it is reasonable to assume that at high substrate concentrations, drug-drug interactions will have no effect on penetration of BCRP substrates through placenta.
Comparing maternal-to-fetal and fetal-to-maternal clearances revealed great asymmetry in favor of fetal-to-maternal direction. This was most evident at low cimetidine concentrations (0.005 µM), where fetal-to-maternal clearance was almost 25 times higher (p < 0.05) than that in the opposite direction ( Fig. 8) . At a concentration of 1000 µM, however, both maternal-tofetal and fetal-to-maternal clearances of cimetidine reached identical values of 0.042 ml/min/g confirming saturation of Bcrp and limited role of its efflux activity. This experimental value corresponds well with the calculated clearance of passive diffusion (Cl pd ~ 0.041 -0.043 ml/min/g), see Table 2 .
Bcrp transports cimetidine from fetus to mother against concentration gradient
To investigate the potential of Bcrp to remove its substrate from fetal circulation, 
DISCUSSION
Detailed knowledge of transplacental kinetics of drugs is essential with respect to fetal safety, fetal medication and drug-drug interactions during pregnancy. Apart from physicalchemical properties, placental passage of many drugs is controlled by interactions with biotransformation enzymes and/or efflux transporters. It is widely believed that enzymes and drug efflux transporters form an active component of the placental barrier that helps protect fetus against maternal toxins (Marin et al., 2004) . In addition, it seems plausible, that these proteins may, to at least some extent, actively metabolize/transport compounds already present in the fetal circulation. Using rat placental perfusion, we have previously demonstrated that 11β-hydroxysteroid dehydrogenase type 2 metabolizes both maternal and fetal corticosterone with a comparable potency . Similarly, P-gp has been confirmed to favor fetal-to-maternal transport of its substrates in perfused rat (Pavek et al., 2003) or human placenta (Molsa et al., 2005; Sudhakaran et al., 2005) . In the present study, we focused on functional analysis of the latest of ABC drug efflux transporters, Bcrp, using dually perfused rat term placenta and rat placenta-derived cell line, HRP-1.
To date, only few studies have reported on BCRP activity in placenta and these are mainly based on in vitro models. Very recently, Kolwankar et al (Kolwankar et al., 2005) employed placental microvillous membrane vesicles to confirm BCRP function in the human placenta. Subsequently, we have described BCRP expression, localization and function in an in vitro placental model, BeWo cell line . In the present study, we used rat placental HRP-1 cell line derived from placental labyrinth region at midgestation (Soares et al., 1987) . This cell line has previously been employed to study several aspects of placental physiology (Soares et al., 1989; Shi et al., 1997; Morris Buus and Boockfor, 2004) , metabolism (Xu et al., 2005) or nutrient transport (Novak et al., 2001; Zhou et al., 2003) . To our knowledge, however, no studies have been performed so far to investigate expression This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on June 29, 2006 as DOI: 10.1124 at ASPET Journals on May 3, 2016 jpet.aspetjournals.org Downloaded from and/or activity of ABC drug efflux transporters in this in vitro placental model. Bcrp expression was revealed at both mRNA and protein levels. Surprisingly, we did not detect any expression of mdr1a or mdr1b genes coding for rat P-gp, neither did we find any signal by Western blotting. Consistent with gene and protein expression results, uptake studies revealed only Bcrp activity, while P-gp did not affect cell accumulation of BODIPY FL prazosin.
These data are similar to what has previously been observed in human choriocarcinoma cell line BeWo (Atkinson et al., 2003; Evseenko et al., 2006) where only BCRP was found to be functionally expressed, while P-gp activity was negligible. Lack of expression and function of P-gp in the HRP-1 cell line makes this model inappropriate to investigate the transplacental transport of P-gp substrates. On the other hand, it may well serve as a tool to study Bcrp role in transplacental pharmacokinetics as its efflux activity will not interfere with that of P-gp.
The only functional in vivo studies on Bcrp activity in the placenta so far have been performed in transgenic mice (Jonker et al., 2000; Jonker et al., 2002) ; however, detailed evaluation of BCRP role in transplacental pharmacokinetics is still lacking. In the present study, cimetidine was employed to comprehensively describe the role of Bcrp in maternal-tofetal and fetal-to-maternal transport. Cimetidine was chosen as a model substrate for its convenient properties: it is a BCRP substrate which is not recognized by human P-gp , it weakly binds to plasma proteins, and its biotransformation by placental enzymes is negligible (Schenker et al., 1987) . In addition, cimetidine passive diffusion through biological membranes is delayed by its physical-chemical properties as shown in transepithelial passage or placental transport (Ching et al., 1987; Schenker et al., 1987) ; this seems to be an important feature to study substrate interactions with an efflux transporter (Eytan et al., 1996; Lentz et al., 2000) . This article has not been copyedited and formatted. The final version may differ from this version. The localization of Bcrp on the apical, maternal-facing membrane of the rat placenta closely resembles that of P-gp described in our earlier studies (Pavek et al., 2003; Novotna et al., 2004) . This finding suggests that Bcrp is, like P-gp, important in preventing entry of potential toxins into the fetal compartment. This assumption has been functionally validated in the present study by means of rat perfused placenta: at low cimetidine concentrations (0.005 µM), maternal-to-fetal clearance was 25-fold lower than clearance in the opposite direction. These data confirm that Bcrp causes asymmetry in transplacental clearances in rats by returning substrates coming from maternal side and facilitating transport of drugs from fetus to mother. Interestingly, pharmacokinetic modeling revealed Michaelis-Menten constant for fetal-to-maternal direction to be 20 times higher than that for maternal-to-fetal direction.
We assume this difference is caused by polarized localization of Bcrp on the maternal side of the placenta; as a result, a compound administered to the fetal circulation needs to pass through fetal tissues to reach the transporter. This suggests that much higher cimetidine concentrations are needed to saturate Bcrp transporter during fetal-to-maternal passage than in the opposite direction.
To investigate the potential of Bcrp to remove drugs already present in the fetal compartment, both maternal and fetal sides of the placenta were perfused with equal concentrations of cimetidine and fetal perfusate was re-circulated. After short equilibration period, we observed significant decrease in fetal cimetidine concentrations, confirming that Bcrp can actively remove its substrate from the fetal compartment. Since decrease in cimetidine concentration continued even at later intervals (dropping by more than 50 % within 60 minutes of perfusion), it is evident that Bcrp in rats can pump this compound from fetus to mother even against concentration gradient.
Interestingly, several studies on cimetidine placental transfer were published two decades ago with intriguing results. When studied in sheep, large cimetidine gradient between mother This article has not been copyedited and formatted. The final version may differ from this version. (Mihaly et al., 1983) . In a follow-up study, the authors suggested that an active transporter from the fetal to the maternal circulation might be responsible for this discrepancy (Ching et al., 1985) . In contrast, when investigated in the dually perfused human placenta, two papers concluded that transport of cimetidine was very slow and occurred by passive diffusion with lack of saturation kinetics (Ching et al., 1987; Schenker et al., 1987) .
These contrasting findings might be explained by interspecies differences; however, one has to realize that these studies were performed before efflux transporters were discovered and described, with limited range of cimetidine concentrations, and without the option to use appropriate inhibitors. Therefore, possible role of a drug efflux transporter in the transplacental pharmacokinetics of cimetidine could not have been taken in account. Our present findings suggest that Bcrp is the transporter responsible for limited maternal-to-fetal passage and large maternal/fetal concentration ratio of cimetidine in rats. However, BCRP activity in perfused placentas of other species must be elucidated before a final conclusion is drawn.
Regarding BCRP expression in human tissues, relatively high mRNA levels were observed in placenta, liver and small intestine with lower expression in the kidney, heart and brain (Doyle et al., 1998) . In rodents, on the other hand, different mRNA distribution pattern was indicated by Tanaka et al (Tanaka et al., 2005) who found high expression levels in kidney, small and large intestine while lower levels were found in other tissues including brain and placenta. Based on these observations, the authors suggested limited importance of placental Bcrp in rodents (Tanaka et al., 2005) . In contrast, functional role of placental Bcrp has been proposed in mice by Jonker et al (Jonker et al., 2000; Jonker et al., 2002) and thoroughly assessed in the rat placenta in our study. Therefore, mRNA expression levels do not have to necessarily correlate with transport potency of the protein since there is a number of other factors that will determine its functional activity, such as posttranscriptional/ This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, functional expression of Bcrp in the rat placenta and rat placental HRP-1 cell line was confirmed in this study. A pharmacokinetic model was applied to distinguish between passive and Bcrp-mediated placental transport of cimetidine as a model substrate.
We provide evidence for striking asymmetry between maternal-to-fetal and fetal-to-maternal transport of cimetidine; this difference is partly lowered by addition of BCRP inhibitors and completely abolished at high substrate concentrations. In addition, using closed perfusion system on the fetal side of the placenta, we are the first to demonstrate that Bcrp, despite being localized on the maternal-facing side, actively removes cimetidine from the fetal circulation against concentration gradient. Based on our findings, we propose a two-level defensive role of placental BCRP: the transporter (i) reduces passage of its substrates from mother to fetus but also (ii) removes the drug already present in the fetal circulation even Pharmacokinetic parameters were obtained by fitting experimental data with equations 7 and 8. Cl pd -transplacental clearance occurring by passive diffusion; V max -maximal velocity of Bcrp mediated transport; K m -concentration of cimetidine at which half the maximal velocity is reached. GF120918 (2 µM) added to the maternal compartment was used as an inhibitor
